Understanding how T-cell leukemia responds to dasatinib treatment

Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia

NIH-funded research St. Jude Children's Research Hospital · NIH-10873128

This study is looking at how well the drug dasatinib works for kids with T-cell acute lymphoblastic leukemia (T-ALL) and aims to find out which children are most likely to benefit from it, so we can tailor treatments to help them fight this tough cancer better.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionSt. Jude Children's Research Hospital NIH-funded
Lab location1 site (Memphis, United States)
Project IDNIH-10873128 on NIH RePORTER

What this research studies

This research investigates the response of pediatric T-cell acute lymphoblastic leukemia (T-ALL) to the drug dasatinib. It aims to identify specific biomarkers that can predict which patients will benefit from this treatment and to understand the mechanisms behind resistance to the drug. By using a systems biology approach, the study integrates genomic data with functional drug testing to develop a model that can guide personalized treatment strategies for children with T-ALL. The ultimate goal is to improve treatment outcomes for these patients who often have aggressive forms of leukemia.

Who could benefit from this research

Good fit: Ideal candidates for this research are children diagnosed with T-cell acute lymphoblastic leukemia who may be eligible for dasatinib treatment.

Not a fit: Patients with other types of leukemia or those who do not have T-cell acute lymphoblastic leukemia may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective treatment options for children with T-ALL, potentially improving survival rates and reducing the risk of relapse.

How similar studies have performed: Previous research has shown promising results in using targeted therapies like dasatinib for certain leukemia types, indicating potential for success in this novel approach.

Where this research is happening

Memphis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.